Clinical utility
study results

Percepta bronchial classifier down classification of risk can decrease additional invasive procedures.

Percepta bronchial classifier can down classify a nodule’s risk of malignancy and decrease additional invasive procedures by 61% at 12 months.1
Diagram of a clinical utility study for patients with intermediate and low risk patients. 74% of patients had a change in management plan from invasive to surveillance after a down-classified result. 61% continued to undergo surveillance at 12 months.

Percepta GSC expanded clinical utility in patients with early-stage lung cancer.

The Percepta GSC test can accelerate the delivery of curative therapy in patients with a high pre-test risk result that have been up classified to a high risk with a 91% positive predictive value.2
Bar graph showing change in post-test intervention steps after a Percepta GCS test. Pre-test, only 17% of patients received a recommendation for ablative therapy, compared to 56% of patients post-test, corresponding to a 39% increase in recommendation for ablative therapy/surgery.

Real world evidence with Percepta GSC

Raval et al. reviews data from his institution that demonstrates how Percepta GSC has helped manage patients. The Percepta GSC test can provide additional information when bronchoscopy is inconclusive with a high NPV for a low result and a high PPV for a high result to guide clinical decision making.

Hear from peers

Discover what key opinion leaders are saying about Percepta GSC in case studies, testimonials or on-demand presentations.


1. Lee H, et al. CHEST, 2020.
2. Sethi S, et al. BMC Pulm Med. 22, 26, 2022.